FULC Q1 2025 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$20M

Net Income

-$18M

EPS (Diluted)

$-0.28

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$243M

Total Liabilities

$14M

Stockholders' Equity

$228M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$479,000	+100.0%
Operating Income	-$20M	-$30M	+31.6%
Net Income	-$18M	-$27M	+34.3%